Effects of obstetric factors and storage temperatures on the yield of endothelial colony forming cells from umbilical cord blood

Coldwell, Kate E.; Lee, Stephanie J.; Kean, Jennifer; Khoo, Cheen P.; Tsaknakis, Grigorios; Smythe, Jon; Watt, Suzanne M.

doi:10.1007/s10456-011-9222-4

Cited by 19 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We and others have observed that circulating CB and PB ECFC-derived cells exhibit differences in cell proliferation and vascular tubule formation35611. Therefore, in this study, we investigated differences in the post-transcriptional regulation of circulating CB and PB ECFC-derived cells by comparing their microRNA profiles.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

miR-193a-3p interaction with HMGB1 downregulates human endothelial cell proliferation and migration

Khoo

Roubelakis

Schrader

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Circulating endothelial colony forming cells (ECFCs) contribute to vascular repair where they are a target for therapy. Since ECFC proliferative potential is increased in cord versus peripheral blood and to define regulatory factors controlling this proliferation, we compared the miRNA profiles of cord blood and peripheral blood ECFC-derived cells. Of the top 25 differentially regulated miRNAs selected, 22 were more highly expressed in peripheral blood ECFC-derived cells. After validating candidate miRNAs by q-RT-PCR, we selected miR-193a-3p for further investigation. The miR-193a-3p mimic reduced cord blood ECFC-derived cell proliferation, migration and vascular tubule formation, while the miR-193a-3p inhibitor significantly enhanced these parameters in peripheral blood ECFC-derived cells. Using in silico miRNA target database analyses combined with proteome arrays and luciferase reporter assays of miR-193a-3p mimic treated cord blood ECFC-derived cells, we identified 2 novel miR-193a-3p targets, the high mobility group box-1 (HMGB1) and the hypoxia upregulated-1 (HYOU1) gene products. HMGB1 silencing in cord blood ECFC-derived cells confirmed its role in regulating vascular function. Thus, we show, for the first time, that miR-193a-3p negatively regulates human ECFC vasculo/angiogenesis and propose that antagonising miR-193a-3p in less proliferative and less angiogenic ECFC-derived cells will enhance their vasculo/angiogenic function.

show abstract

Section: Discussionmentioning

confidence: 98%

“…In the human, ECFCs from healthy perinatal CB are significantly more frequent than those found circulating in healthy adult PB and have a higher proliferative capacity3561115161819. Thus, defining strategies to enhance the content of these cells in the adult, while retaining their vasculogenic/angiogenic functions would be beneficial.…”

mentioning

confidence: 99%

miR-193a-3p interaction with HMGB1 downregulates human endothelial cell proliferation and migration

Khoo

Roubelakis

Schrader

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…In order to be able to utilize blood-derived ECs for therapeutic applications with patients suffering from cardiovascular and peripheral vascular diseases, a simple method is needed that can yield at least one colony of 2000 or more ECs from small volumes of blood. 9,16 Furthermore, in order to prevent potential risks of interspecies immunoreactions and transmission of infectious agents, a method that eliminates animal-derived products to the greatest extent possible is desired.…”

Section: Introductionmentioning

confidence: 99%

Isolation of Functional Human Endothelial Cells from Small Volumes of Umbilical Cord Blood

et al. 2013

View full text Add to dashboard Cite

Endothelial cells (ECs) isolated from endothelial progenitor cells in blood have great potential as a therapeutic tool to promote vasculogenesis and angiogenesis and treat cardiovascular diseases. However, current methods to isolate ECs are limited by a low yield with few colonies appearing during isolation. In order to utilize blood-derived ECs for therapeutic applications, a simple method is needed that can produce a high yield of ECs from small volumes of blood without the addition of animal-derived products. For the first time, we show that human endothelial cells can be isolated without the prior separation of blood components through the technique of diluted whole blood incubation (DWBI) utilizing commercially available human serum. We isolated ECs from small volumes of blood (~ 10 ml) via DWBI and characterized them with flow cytometry, immunohistochemistry, and uptake of DiI-labeled acetylated low density lipoprotein (DiI-Ac-LDL). These ECs are functional as demonstrated by their ability to form tubular networks in Matrigel, adhere and align with flow under physiological fluid shear stress, and produce increased nitric oxide under fluid flow. An average of 7.0 ± 2.5 EC colonies that passed all functional tests described above were obtained per 10 ml of blood as compared to only 0.3 ± 0.1 colonies with the traditional method based on density centrifugation. The time until first colony appearance was 8.3 ± 1.2 days for ECs isolated with the DWBI method and 12 ± 1.4 days for ECs isolated with the traditional isolation method. A simplified method, such as DWBI, in combination with advances in isolation yield could enable the use of blood-derived ECs in clinical practice.

show abstract

“…EPCs can be divided into two types, the early EPCs and the late EPCs. Some researches called the late EPCs as EPC-derived endothelial cells (EPC-derived ECCs) or endothelial-colony-forming cells [12]. In our study, we chose EPCs of 1-6 generation as the experimental cells because of their higher capacity of proliferation and tube formation than those in the early EPCs.…”

Section: Discussionmentioning

confidence: 99%

Antitumor effects of Endostar on non-Hodgkin's lymphoma by regulating endothelial progenitor cells through protein kinase B-dependent pathway

Yu¹,

Wu²,

Yang³

et al. 2013

ABBS

View full text Add to dashboard Cite

Endothelial progenitor cells (EPCs) play an important role in non-Hodgkin's lymphoma (NHL) development. Endostar is an anti-angiogenic drug designed to stop cancer by nullifying a tumor's ability to obtain oxygen and nutrients. In this study, we examined the anti-angiogenic activities of Endostar on NHL cell lines and murine xenograft model of NHL in vitro and in vivo, respectively, and explored the underlying antiangiogenic mechanism of Endostar. Results showed that Endostar may inhibit the EPC proliferation by reducing the expression of p-protein kinase B, but not p-ERK expression. Our finding could lead to a better understanding of the effects of Endostar on NHL.

show abstract

Effects of obstetric factors and storage temperatures on the yield of endothelial colony forming cells from umbilical cord blood

Cited by 19 publications

References 44 publications

miR-193a-3p interaction with HMGB1 downregulates human endothelial cell proliferation and migration

miR-193a-3p interaction with HMGB1 downregulates human endothelial cell proliferation and migration

Isolation of Functional Human Endothelial Cells from Small Volumes of Umbilical Cord Blood

Antitumor effects of Endostar on non-Hodgkin's lymphoma by regulating endothelial progenitor cells through protein kinase B-dependent pathway

Contact Info

Product

Resources

About